Results 41 to 50 of about 9,650,806 (331)

Microglia in Parkinson’s Disease

Journal of Parkinson's Disease, 2022
Microglia are the primary resident immune cells of the central nervous system. Neuropathological reports have identified augmented microglial activation in brains of patients with neurodegenerative disorders including Parkinson’s disease (PD).
N. Stefanova
semanticscholar   +1 more source

Randomized controlled trial of a home-based action observation intervention to improve walking in Parkinson disease [PDF]

, 2016
Published in final edited form as: Arch Phys Med Rehabil. 2016 May ; 97(5): 665–673. doi:10.1016/j.apmr.2015.12.029.OBJECTIVE: To examine the feasibility and efficacy of a home-based gait observation intervention for improving walking in Parkinson ...
Cronin-Golomb, Alice, Ellis, Terry D., Jaywant, Abhishek, Lin, Cheng-Chieh, Neargarder, Sandy, Roy, Serge   +5 more
core   +1 more source

Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease

Frontiers in Cell and Developmental Biology, 2020
Parkinson disease, the second most common movement disorder, is a complex neurodegenerative disorder hallmarked by the accumulation of alpha-synuclein, a neural-specific small protein associated with neuronal synapses. Mutations in the glucocerebrosidase
Tae-Un Han, Richard Sam, Ellen Sidransky
doaj   +1 more source

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background In addition to primary neurodegenerative processes, vascular disorders, such as stroke, can lead to parkinsonism. However, some cardiovascular risk factors, such as smoking and elevated cholesterol levels, are associated with reduced risk of ...
Jens Sundbøll, Szimonetta Komjáthiné Szépligeti, Péter Szentkúti, Kasper Adelborg, Erzsébet Horváth‐Puhó, Lars Pedersen, Victor W. Henderson, Henrik Toft Sørensen   +7 more
doaj   +1 more source

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

JAMA Neurology, 2020
Key Points Question Does ambroxol cross the blood-brain barrier, and what are the biochemical changes associated with ambroxol therapy in patients with Parkinson disease with and without glucocerebrosidase gene mutations?
S. Mullin, Laura Smith, Katherine Lee, G. D'Souza, Philip Woodgate, Josh Elflein, J. Hällqvist, M. Toffoli, A. Streeter, Joanne Hosking, W. Heywood, R. Khengar, Philip Campbell, Jason Hehir, Sarah Cable, K. Mills, H. Zetterberg, P. Limousin, V. Libri, T. Foltynie, A. Schapira   +20 more
semanticscholar   +1 more source

Reversing Parkinson Disease Model with in situ Converted Nigral Neurons

Nature, 2020
Parkinson’s disease is characterized by loss of dopamine neurons in the substantia nigra1. Similar to other major neurodegenerative disorders, there are no disease-modifying treatments for Parkinson’s disease.
Hao Qian, Xinjiang Kang, Jing Hu, Dongyang Zhang, Zhengyu Liang, Fan Meng, Xuan Zhang, Yuanchao Xue, R. Maimon, S. Dowdy, N. Devaraj, Zhuan Zhou, W. Mobley, D. Cleveland, Xiang-Dong Fu   +14 more
semanticscholar   +1 more source

Are the digit ratio (2D:4D) and hand grip strength related to Parkinson disease in elderly males?

BMC Sports Science, Medicine and Rehabilitation, 2023
Background Sex hormones affect the pathogenesis of Parkinson patients and it has been suggested that gender is the most important factor in the development and progression of Parkinson’s disease.
Hamid Arazi, Roghayeh Bavafa Birak Olia, Ehsan Eghbali   +2 more
doaj   +1 more source

Role of mitochondria in Parkinson disease [PDF]

, 1999
The cause of the selective degeneration of nigrostriatal neurons in Parkinson disease (PD) has remained largely unknown. Exceptions include rare missense mutations in the alpha-synuclein gene on chromosome 4, a potentially pathogenic mutation affecting ...
Graeber, M. B., Hofhaus, G., Kösel, S., Maassen, A., Vieregge, P.   +4 more
core   +1 more source

Highly challenging balance program reduces fall rate in Parkinson disease [PDF]

, 2016
Published in final edited form as: J Neurol Phys Ther. 2016 January ; 40(1): 24–30. doi:10.1097/NPT.0000000000000111BACKGROUND AND PURPOSE: There is a paucity of effective treatment options to reduce falls in Parkinson disease (PD).
DeAngelis, Tamara R., Ellis, Terry, Hendron, Kathryn, Saint-Hilaire, Marie, Sparrow, David, Thomas, Cathi A.   +5 more
core   +1 more source

Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021

British medical journal
Objective To predict the global, regional, and national prevalence of Parkinson’s disease by age, sex, year, and Socio-demographic Index to 2050 and quantify the factors driving changes in Parkinson’s disease cases. Design Modelling study.
Dongning Su, Yu-Ling Cui, Chengzhang He, P. Yin, Ruhai Bai, Jinqiao Zhu, Joyce S. T. Lam, Junjiao Zhang, Rui Yan, Xiaoqing Zheng, Jiayi Wu, Dong Zhao, Anxin Wang, Maigeng Zhou, Tao Feng   +14 more
semanticscholar   +1 more source